DXSE:F:F-Xtrackers Stoxx Europe 600 Health Care Swap UCITS ETF 1C (EUR)

ETF | Others |

Last Closing

USD 223.55

Change

0.00 (0.00)%

Market Cap

USD 0.14B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-04 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

+0.07 (+0.27%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

+0.11 (+0.22%)

USD 113.22B
SXR8:F iShares Core S&P 500 UCITS ETF..

-1.30 (-0.25%)

USD 83.51B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

+0.13 (+0.25%)

USD 77.76B
FRCJ:F UBS MSCI Japan Socially Respon..

+0.05 (+0.21%)

USD 73.13B
EUNL:F iShares Core MSCI World UCITS ..

-0.07 (-0.07%)

USD 72.04B
SXRZ:F iShares VII PLC - iShares Nikk..

-0.45 (-0.20%)

USD 56.29B
XDNY:F Xtrackers MSCI Japan ESG Scree..

+0.04 (+0.28%)

USD 54.81B
VUAA:F Vanguard S&P 500 UCITS Acc

N/A

USD 51.63B
VUSA:F Vanguard Funds Public Limited ..

-0.24 (-0.25%)

USD 51.63B

ETFs Containing DXSE:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.34% 77% C+ 69% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.34% 74% C 64% D
Trailing 12 Months  
Capital Gain 8.41% 54% F 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.41% 52% F 54% F
Trailing 5 Years  
Capital Gain 65.27% 84% B 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 65.27% 83% B 64% D
Average Annual (5 Year Horizon)  
Capital Gain 8.73% 78% C+ 73% C
Dividend Return 8.73% 77% C+ 67% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.42% 66% D+ 85% B
Risk Adjusted Return 103.74% 99% N/A 97% N/A
Market Capitalization 0.14B 35% F 35% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.